益生菌
免疫系统
炎症
医学
社会心理的
疾病
炎症反应
免疫学
肠易激综合征
肠道菌群
肠-脑轴
生物信息学
萧条(经济学)
海马结构
神经科学
大肠杆菌
第一行
活性氧
失调
炎症性肠病
神经系统
主机响应
免疫
克罗恩病
输送系统
作者
Jiali Yang,Xueqian Liu,Hongyi Ma,Guoling Feng,Yujia Guo,Shenghan Zhang,Haotian Yu,Di Zhao,Le Qu,Ning Song,Zhenzhong Zhang,Jinjin Shi,Yifei Wang,Junxia Xie
标识
DOI:10.1016/j.apsb.2026.10.030
摘要
Individuals with inflammatory bowel disease (IBD) are particularly susceptible to psychosocial disturbances, including depression and anxiety. Unfortunately, conventional antidepressants have shown limited efficacy in managing IBD-associated psychosocial disorders, largely due to the intrinsic nature of intestinal diseases and the complex bidirectional communication between the gut and the brain. Herein, we armed the probiotic Escherichia coli Nissle 1917 (EcN) with gamma-aminobutyric acid (GABA)–chitosan nanoparticles (GC NPs) to form a “mutualistic probiotic–drug” oral-delivery system (GC-EcN) for reshaping a healthy microbiota–gut–brain axis. The intestinal colonization ability of the probiotic facilitated the targeted delivery and retention of the nanoparticles, thereby enabling sustained GABA release and the scavenging of excess reactive oxygen species. The resulting reduction in inflammation enhanced bacterial viability, rapidly restored intestinal–barrier function, and rebalanced the gut microbiota. Notably, GC-EcN alleviated anxiety- and depression-like behaviors through the microbiota–gut–brain axis by reducing neuroinflammation, enhancing hippocampal neural plasticity, and modulating immune responses in the hippocampus. This study highlights the critical role of the microbiota–gut–brain axis in the progression of IBD-associated psychiatric comorbidities and proposes a safe, simple, and effective therapeutic approach for managing both IBD and its associated mental disorders.
科研通智能强力驱动
Strongly Powered by AbleSci AI